BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25824455)

  • 1. Immune checkpoint inhibition in lymphoid disease.
    Eyre TA; Collins GP
    Br J Haematol; 2015 Aug; 170(3):291-304. PubMed ID: 25824455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
    Ramsay AG
    Br J Haematol; 2013 Aug; 162(3):313-25. PubMed ID: 23691926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint blockade in lymphoid malignancies.
    Thanarajasingam G; Thanarajasingam U; Ansell SM
    FEBS J; 2016 Jun; 283(12):2233-44. PubMed ID: 26807978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients.
    Linedale R; Schmidt C; King BT; Ganko AG; Simpson F; Panizza BJ; Leggatt GR
    PLoS One; 2017; 12(4):e0175755. PubMed ID: 28423034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers for checkpoint inhibition in hematologic malignancies.
    Atanackovic D; Luetkens T
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):198-206. PubMed ID: 29775689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword.
    Hobo W; Hutten TJA; Schaap NPM; Dolstra H
    Br J Haematol; 2018 Apr; 181(1):38-53. PubMed ID: 29318591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.
    Moreno-Cubero E; Larrubia JR
    World J Gastroenterol; 2016 Jul; 22(28):6469-83. PubMed ID: 27605882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immune-checkpoint inhibitors in hematologic malignancies].
    Maruyama D
    Rinsho Ketsueki; 2016; 57(11):2381-2387. PubMed ID: 27941289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programming the immune checkpoint to treat hematologic malignancies.
    Vick E; Mahadevan D
    Expert Opin Investig Drugs; 2016 Jul; 25(7):755-70. PubMed ID: 27070269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Checkpoint blockade in lymphoma.
    Armand P
    Hematology Am Soc Hematol Educ Program; 2015; 2015():69-73. PubMed ID: 26637703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint blockade therapy: the 2014 Tang Prize in Biopharmaceutical Science.
    Chen YS; Shen CR
    Biomed J; 2015; 38(1):5-8. PubMed ID: 25673064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint blocking antibodies in cancer immunotherapy.
    Kyi C; Postow MA
    FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors in lung cancer: past, present and future.
    Seetharamu N; Budman DR; Sullivan KM
    Future Oncol; 2016 May; 12(9):1151-63. PubMed ID: 27019997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1 /PD-L1 checkpoint in hematological malignancies.
    Annibali O; Crescenzi A; Tomarchio V; Pagano A; Bianchi A; Grifoni A; Avvisati G
    Leuk Res; 2018 Apr; 67():45-55. PubMed ID: 29428449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8
    Hutten TJA; Norde WJ; Woestenenk R; Wang RC; Maas F; Kester M; Falkenburg JHF; Berglund S; Luznik L; Jansen JH; Schaap N; Dolstra H; Hobo W
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):666-677. PubMed ID: 29197680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint blockade in hematologic malignancies.
    Armand P
    Blood; 2015 May; 125(22):3393-400. PubMed ID: 25833961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies.
    Wang H; Kaur G; Sankin AI; Chen F; Guan F; Zang X
    J Hematol Oncol; 2019 Jun; 12(1):59. PubMed ID: 31186046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [PD-1 blockade therapy in lymphoid malignancies].
    Nishikori M; Takaori-Kondo A
    Rinsho Ketsueki; 2017; 58(10):2043-2049. PubMed ID: 28978847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.
    Howell M; Lee R; Bowyer S; Fusi A; Lorigan P
    Lung Cancer; 2015 May; 88(2):117-23. PubMed ID: 25776466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant.
    Merryman RW; Armand P
    Curr Hematol Malig Rep; 2017 Feb; 12(1):44-50. PubMed ID: 28155012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.